
FIRST CHOICE NEXT

MAY 15TH, 2023 FORMULARY UPDATE

Formulary Changes

The following products will be added to the formulary:

1. Additions to Tier 4 with PA:
 - a. Radicava ORS
 - b. Lanreotide 120 mg/0.5mL
 - c. Sotyktu
 - d. Rezlidhia
 - e. Krazati
 - f. Turalio
 - g. Jaypirca
 - h. Orserdu
 - i. Amjevita
2. Additions to Tier 3:
 - a. Atrovent HFA
3. Additions to Tier 1 with ST:
 - a. Tafluprost 0.0015% ophthalmic solution
4. Additions to Tier 1:
 - a. Amlodipine-olmesartan oral tablets
 - b. Amlodipine-valsartan oral tablets

The following products will have quantity limits update:

1. Eliquis 5 mg tablet

The following products will be removed from the formulary:

1. All non-BD pen needles and insulin syringes
 - a. BD pen needles and insulin syringes will be exclusive formulary product
 - b. POS messaging added to non-formulary products-“BD Products Preferred”
2. Humalog 100 U/mL vial, KwikPen, and Junior KwikPen
 - a. Insulin lispro 100 U/mL formulations are available on tier 1
3. Lyumjev 100 U/mL vial and KwikPen and 200 U/mL KwikPen
4. Ilaris
5. Diltiazem Extended Release 12 Hour Oral Capsules (60, 90, and 120 mg)
6. Ilaris
7. Kynmobi
8. Orencia intravenous solution
9. Somatuline Depot 120 mg/0.5 mL
10. Verapamil Extended Release 24 Hour Oral Capsule (100, 200, and 300 mg)
11. Zioptan